These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 25283256)

  • 1. Therapeutic strategies in extrinsic atopic dermatitis: focus on inhibition of IL-4 as a new pharmacological approach.
    Di Lernia V
    Expert Opin Ther Targets; 2015 Jan; 19(1):87-96. PubMed ID: 25283256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10.
    Kaesler S; Volz T; Skabytska Y; Köberle M; Hein U; Chen KM; Guenova E; Wölbing F; Röcken M; Biedermann T
    J Allergy Clin Immunol; 2014 Jul; 134(1):92-9. PubMed ID: 24698321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug evaluation review: dupilumab in atopic dermatitis.
    Hamilton JD; Ungar B; Guttman-Yassky E
    Immunotherapy; 2015; 7(10):1043-58. PubMed ID: 26598956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis.
    Morioka T; Yamanaka K; Mori H; Omoto Y; Tokime K; Kakeda M; Kurokawa I; Gabazza EC; Tsubura A; Yasutomi Y; Mizutani H
    Br J Dermatol; 2009 Jun; 160(6):1172-9. PubMed ID: 19416272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asthma and Atopic Dermatitis: A Review of Targeted Inhibition of Interleukin-4 and Interleukin-13 As Therapy for Atopic Disease.
    Buzney CD; Gottlieb AB; Rosmarin D
    J Drugs Dermatol; 2016 Feb; 15(2):165-71. PubMed ID: 26885783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.
    D'Erme AM; Romanelli M; Chiricozzi A
    Drug Des Devel Ther; 2017; 11():1473-1480. PubMed ID: 28553077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical application of Taglisodog-eum inhibits the development of experimental atopic dermatitis.
    Hwang JS; Kim JE; Kim HT; Yu YB; Im SH
    J Ethnopharmacol; 2013 Jan; 145(2):536-46. PubMed ID: 23211659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical suplatast tosilate (IPD) ameliorates Th2 cytokine-mediated dermatitis in caspase-1 transgenic mice by downregulating interleukin-4 and interleukin-5.
    Murakami T; Yamanaka K; Tokime K; Kurokawa I; Tsutsui H; Nakanishi K; Mizutani H
    Br J Dermatol; 2006 Jul; 155(1):27-32. PubMed ID: 16792748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab for Moderate-to-Severe Atopic Dermatitis.
    Vangipuram R; Tyring SK
    Skin Therapy Lett; 2017 Nov; 22(6):1-4. PubMed ID: 29091379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism underlying the effect of combined therapy using glucosamine and low-dose cyclosporine A on the development of atopic dermatitis-like skin lesions in NC/Nga mice.
    Kim CH; Choi YS; Cheong KA; Lee AY
    Int Immunopharmacol; 2013 Feb; 15(2):424-32. PubMed ID: 23352844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis.
    Kim ST; Lee KM; Park HJ; Jin SE; Ahn WS; Kim CK
    J Gene Med; 2009 Jan; 11(1):26-37. PubMed ID: 19006098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of atopic dermatitis is independent of Immunoglobulin E up-regulation in the K14-IL-4 SKH1 transgenic mouse model.
    Chen L; Overbergh L; Mathieu C; Chan LS
    Clin Exp Allergy; 2008 Aug; 38(8):1367-80. PubMed ID: 18489026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis.
    Raap U; Weißmantel S; Gehring M; Eisenberg AM; Kapp A; Fölster-Holst R
    Pediatr Allergy Immunol; 2012 May; 23(3):285-8. PubMed ID: 22509760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of Ag85B showed therapeutic effects to Th2-type cytokine-mediated acute phase atopic dermatitis by inducing regulatory T cells.
    Mori H; Yamanaka K; Matsuo K; Kurokawa I; Yasutomi Y; Mizutani H
    Arch Dermatol Res; 2009 Feb; 301(2):151-7. PubMed ID: 18633632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effects of streptococcal preparation OK-432 on atopic dermatitis-like lesions in NC/Nga mice: possible shift from a Th2- to Th1-predominance.
    Horiuchi Y; Bae S; Katayama I; Nishioka K
    J Dermatol Sci; 2004 Sep; 35(3):187-97. PubMed ID: 15381240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of OSMRβ signaling ameliorates skin lesions in a mouse model of human atopic dermatitis.
    Komori T; Hisaoka T; Kotaki A; Iwamoto M; Miyajima A; Esashi E; Morikawa Y
    FASEB J; 2024 Jan; 38(1):e23359. PubMed ID: 38102969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow cytometric detection of type 1 (IL-2, IFN-gamma) and type 2 (IL-4, IL-5) cytokines in T-helper and T-suppressor/cytotoxic cells in rheumatoid arthritis, allergic asthma and atopic dermatitis.
    Schuerwegh AJ; De Clerck LS; De Schutter L; Bridts CH; Verbruggen A; Stevens WJ
    Cytokine; 1999 Oct; 11(10):783-8. PubMed ID: 10525317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic pipeline for atopic dermatitis: End of the drought?
    Paller AS; Kabashima K; Bieber T
    J Allergy Clin Immunol; 2017 Sep; 140(3):633-643. PubMed ID: 28887947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory therapies in atopic dermatitis.
    Heratizadeh A; Werfel T
    Allergy; 2016 Dec; 71(12):1666-1675. PubMed ID: 27735066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of the IL-13 pathway in skin inflammation.
    Tubau C; Puig L
    Expert Rev Clin Immunol; 2021 Jan; 17(1):15-25. PubMed ID: 33275064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.